key: cord-0767449-1ehcwczf
authors: Baumann, Tycho; Delgado, Julio; Montserrat, Emili
title: CLL and COVID-19 at the Hospital Clinic of Barcelona: an interim report
date: 2020-05-19
journal: Leukemia
DOI: 10.1038/s41375-020-0870-5
sha: f627ce221159987d034ce3ff7c582ed3c0b64ac4
doc_id: 767449
cord_uid: 1ehcwczf

nan

median follow-up of 420 patients who remain alive is 7.9 years. Four of these patients (0.95%) have been diagnosed with symptomatic COVID-19. Their characteristics and outcome are shown in the Table 1 . Of note, the number of patients with COVID-19 admitted at the Hospital Clinic of Barcelona as of 6 May 2020 is 2366.

All four patients were males, old and suffered from comorbidity; three had increased ferritin levels; two presented lymphocytopenia; and one had increased D-dimer levels, all features associated with poor outcome in COVID-19 [4] . Also, two patients had previously received therapy for CLL. Despite this, the course of the disease was mild, and no patient required admission in an intensive care unit; three patients quickly recovered after 4-8 days and one after 24 days of experimental therapy for COVID-19. It could be speculated that the CLL-related immunodeficiency, rather than exacerbating the effects of SARS-Cov-2 might prevent them [5] . This, as well as the potential role of immunomodulatory agents (e.g., ibrutinib) on the outcome of patients with CLL infected by SARS-Cov-2, deserves investigation [6, 7] .

The concept that patients with cancer have a high-risk for COVID-19 derives from reports describing the underlying conditions in patients with COVID-19 [8, 9] . Ours is the first attempt to directly determining the prevalence of COVID-19 in CLL. In short, 4 of 420 (0.95%) patients, representative of the general CLL population, have been so far diagnosed with mild, symptomatic COVID-19. The seemingly low prevalence of symptomatic COVID-19 in CLL needs to be taken cautiously as the number of cases may increase as long as the pandemic persists. Several recently launched studies, will help to clarify the prevalence of COVID-19 in CLL, its clinical characteristics, optimal therapy, and outcome. Meanwhile, this interim report based on a large series of patients provides a frame to gauge the likely impact of COVID-19 on patients with CLL. Also, different organisms have issued helpful recommendations on the prevention of COVID-19 in patients with CLL or cancer in this dramatic and challenging moment [10, 11] . Ceftriaxone iv (4 days) Teicoplanin iv (4 days) Lopinavir/ritonavir oral (7 days) Hydroxychloroquine oral (5 days)

Azithromycin oral (5 days)

Ceftriaxone iv (2 days) Teicoplanin iv (2 days) Lopinavir/ritonavir oral (2 days) Hydroxychloroquine oral (2 days)

Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

SARS-CoV-2 receptor ACE2 is an interferonstimulated gene in human airway epithelial cells and is detected in specific cell subsets across tissues

Bruton's tyrosine kinase: an emerging key player in innate immunity

The BTK-inhibitor ibrutinib may protect against pulmonary injury in COVID-19 infected patients

Prevalence of underlying diseases in hospitalized patients with COVID-19: a systematic review and meta-analysis

CDC COVID-19 Response Team

ASH recommendations (endorsed by ERIC/EHA)

EHA Infectious Disease Scientific Working Group, et al. Frequently asked questions regarding SARS-CoV2 in cancer patients-recommendations for clinicians caring for patients with malignant diseases

Acknowledgements Thanks are due to Antoni Trilla (Department of Epidemiology, Hospital Clínic Barcelona) and Antoni Castells (Medical Director, Hospital Cínic Barcelona) for helpful information, and to all membres from the COVID-19 Team from the Hospital Clinic Barcelona, patients, and relatives for their exemplary courage.

Conflict of interest The authors declare that they have no conflict of interest.Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.